Literature DB >> 11572861

Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes.

M Russwurm1, N Wittau, D Koesling.   

Abstract

The signaling molecule nitric oxide (NO) exerts most of its effects by the stimulation of the NO-sensitive guanylyl cyclase. Two isoforms of the NO receptor molecule exist: the ubiquitously occurring alpha(1)beta(1) and the alpha(2)beta(1) with a more limited distribution. As the isoforms are functionally indistinguishable, the physiological relevance of these isoforms remained unclear. The neuronal NO synthase has been reported to be associated with PSD-95. Here, we demonstrate the interaction of the so far unnoticed alpha(2)beta(1) isoform with PSD-95 in rat brain as shown by coprecipitation. The interaction is mediated by the alpha(2) C-terminal peptide and the third PDZ domain of PSD-95. As a consequence of the PSD-95 interaction, the so far considered "soluble" alpha(2)beta(1) isoform is recruited to the membrane fraction of synaptosomes, whereas the alpha(1)beta(1) isoform is found in the cytosol. Our results establish the alpha(1)beta(1) as the cytosolic and the alpha(2)beta(1) as the membrane-associated NO-sensitive guanylyl cyclase and suggest the alpha(2)beta(1) isoform as the sensor for the NO formed by the PSD-95-associated neuronal NO synthase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572861     DOI: 10.1074/jbc.M105587200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

Review 1.  Isoforms of NO-sensitive guanylyl cyclase.

Authors:  Michael Russwurm; Doris Koesling
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

2.  There's NO binding like NOS binding: protein-protein interactions in NO/cGMP signaling.

Authors:  Pavel I Nedvetsky; William C Sessa; Harald H H W Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

3.  Synaptic localization of nitric oxide synthase and soluble guanylyl cyclase in the hippocampus.

Authors:  Alain Burette; Ulrike Zabel; Richard J Weinberg; Harald H H W Schmidt; Juli G Valtschanoff
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

4.  Properties of NO-activated guanylyl cyclases expressed in cells.

Authors:  Barry J Gibb; Victoria Wykes; John Garthwaite
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

5.  In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.

Authors:  Florian Mullershausen; Michael Russwurm; Doris Koesling; Andreas Friebe
Journal:  Mol Biol Cell       Date:  2004-07-07       Impact factor: 4.138

6.  Structural and functional insights into the heme-binding domain of the human soluble guanylate cyclase α2 subunit and heterodimeric α2β1.

Authors:  Hongyan Wang; Fangfang Zhong; Jie Pan; Wei Li; Jihu Su; Zhong-Xian Huang; Xiangshi Tan
Journal:  J Biol Inorg Chem       Date:  2012-03-18       Impact factor: 3.358

Review 7.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

8.  Gastric motility in soluble guanylate cyclase alpha 1 knock-out mice.

Authors:  Gwen Vanneste; Ingeborg Dhaese; Patrick Sips; Emmanuel Buys; Peter Brouckaert; Romain A Lefebvre
Journal:  J Physiol       Date:  2007-08-23       Impact factor: 5.182

9.  Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum.

Authors:  Corina Russwurm; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

10.  Role of the soluble guanylyl cyclase alpha1/alpha2 subunits in the relaxant effect of CO and CORM-2 in murine gastric fundus.

Authors:  Ole De Backer; Ellen Elinck; Patrick Sips; Emmanuel Buys; Peter Brouckaert; Romain A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-18       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.